Innovent Biologics Inc - Company Profile
Powered by 
All the data and insights you need on Innovent Biologics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Innovent Biologics Inc Strategy Report
- Understand Innovent Biologics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that carries out the research, development and manufacturing of monoclonal antibodies. It provides products for various diseases such as metabolic, cancer, autoimmune diseases and other therapeutic areas. The company's oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, olverembatinib, ramucirumab, and others. Its autoimmune drugs are adalimumab injection, IBI-353, IBI-112 and IBI-314, among others. The company's metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311
Headquarters
China
Address
168, Dongping Street, Suzhou Industrial Park, Jiangsu, 215123
Website
www.innoventbio.com
No of Employees
4,872
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1801 (HKG)
Revenue (2022)
$877.5M
36.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
52.8%
(2022 vs 2021)
Market Cap*
$7.7B
Net Profit Margin (2022)
XYZ
65.4%
(2022 vs 2021)
* As of and is in US$
Innovent Biologics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oncology Drugs | TYVYT |
| Auto Immune Drugs | BYVASDA |
| Ophthalmology Drugs | SULINNO |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into a partnership with HUTCHMED (China) Limited to introduce a New Drug Application for the combination of fruquintinib and sintilimab to treat patients with advanced endometrial cancer with pMMR1 or non-MSI-H2 tumors. |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with ImmVirX to estimate the combination therapy of ImmVirX’s investigational oncolytic virus IVX037 with TYVYT. |
| 2024 | Others | In February, the company's new drug application was accepted by the Center for Drug Evaluation of the National Medical Products Administration of China for mazdutide. |
Competitor Comparison
| Key Parameters | Innovent Biologics Inc | WuXi Biologics Cayman Inc | Hainan Haiyao Co Ltd | BeiGene (Beijing) Co Ltd | Beijing Tri-Prime Genetic Engineering Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Suzhou | Wuxi | Haikou | Beijing | Beijing |
| State/Province | Jiangsu | Jiangsu | Hainan | Beijing | Beijing |
| No. of Employees | 4,872 | 12,740 | 2,247 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| De-Chao Michael Yu | Chief Executive Officer; Chairman | Executive Board | - | 59 |
| Ronald Ede | Director; Chief Financial Officer | Executive Board | 2017 | 64 |
| Changshou Gao | Senior Vice President; Chief Technology Officer | Senior Management | - | - |
| Vivian Zhang | Chief People Officer | Senior Management | - | - |
| Yongjun Liu | President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward